A310210 Stock Overview
Researches, develops, and discovers small molecule kinase inhibitors in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Voronoi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩85,500.00 |
| 52 Week High | ₩125,900.00 |
| 52 Week Low | ₩28,350.00 |
| Beta | 1.83 |
| 11 Month Change | -26.99% |
| 3 Month Change | 27.99% |
| 1 Year Change | 124.41% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 249.57% |
Recent News & Updates
Health Check: How Prudently Does Voronoi (KOSDAQ:310210) Use Debt?
Sep 20
Is Voronoi (KOSDAQ:310210) Using Too Much Debt?
May 28Shareholder Returns
| A310210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -19.6% | -4.0% | -0.7% |
| 1Y | 124.4% | 23.9% | -4.1% |
Return vs Industry: A310210 exceeded the KR Biotechs industry which returned 23.9% over the past year.
Return vs Market: A310210 exceeded the KR Market which returned -4.1% over the past year.
Price Volatility
| A310210 volatility | |
|---|---|
| A310210 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A310210's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A310210's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 126 | n/a | voronoi.io |
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer.
Voronoi, Inc. Fundamentals Summary
| A310210 fundamental statistics | |
|---|---|
| Market cap | ₩1.63t |
| Earnings (TTM) | -₩36.07b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-41.9x
P/E RatioIs A310210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A310210 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩36.07b |
| Earnings | -₩36.07b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04k |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.6% |
How did A310210 perform over the long term?
See historical performance and comparison